1. Home
  2. COLL vs EEX Comparison

COLL vs EEX Comparison

Compare COLL & EEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
  • EEX
  • Stock Information
  • Founded
  • COLL 2002
  • EEX 2013
  • Country
  • COLL United States
  • EEX United States
  • Employees
  • COLL N/A
  • EEX N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • EEX Advertising
  • Sector
  • COLL Health Care
  • EEX Consumer Discretionary
  • Exchange
  • COLL Nasdaq
  • EEX Nasdaq
  • Market Cap
  • COLL 958.8M
  • EEX 910.8M
  • IPO Year
  • COLL 2015
  • EEX 2017
  • Fundamental
  • Price
  • COLL $37.03
  • EEX $4.91
  • Analyst Decision
  • COLL Strong Buy
  • EEX Strong Buy
  • Analyst Count
  • COLL 4
  • EEX 2
  • Target Price
  • COLL $44.25
  • EEX $7.95
  • AVG Volume (30 Days)
  • COLL 380.6K
  • EEX 53.6K
  • Earning Date
  • COLL 08-07-2025
  • EEX 08-04-2025
  • Dividend Yield
  • COLL N/A
  • EEX 1.22%
  • EPS Growth
  • COLL N/A
  • EEX N/A
  • EPS
  • COLL 1.06
  • EEX 0.04
  • Revenue
  • COLL $707,007,000.00
  • EEX $432,600,000.00
  • Revenue This Year
  • COLL $20.47
  • EEX $14.85
  • Revenue Next Year
  • COLL $2.91
  • EEX $6.42
  • P/E Ratio
  • COLL $35.07
  • EEX $133.67
  • Revenue Growth
  • COLL 22.61
  • EEX 9.96
  • 52 Week Low
  • COLL $23.23
  • EEX $3.22
  • 52 Week High
  • COLL $42.29
  • EEX $6.65
  • Technical
  • Relative Strength Index (RSI)
  • COLL 69.53
  • EEX 48.82
  • Support Level
  • COLL $29.70
  • EEX $4.60
  • Resistance Level
  • COLL $38.24
  • EEX $5.11
  • Average True Range (ATR)
  • COLL 1.23
  • EEX 0.20
  • MACD
  • COLL 0.71
  • EEX -0.01
  • Stochastic Oscillator
  • COLL 87.29
  • EEX 52.72

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About EEX Emerald Holding Inc.

Emerald Holding Inc is a business-to-business (B2B) event organizer principally in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry; the Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. The Majority of the revenue for the company is generated from its Connections segment.

Share on Social Networks: